ProKidney (PROK) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed ProKidney (PROK) over the past year, gaining 52.3% versus a loss of 47.0%. Over five years, TECX leads with a -67.4% price change compared with -84.1% for PROK. ProKidney is the larger company by market cap ($636.7 million vs $425.4 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | TECX |
|---|---|---|
| Share price | $1.60 | $21.76 |
| Market cap | $636.70M | $425.39M |
| 1-day change | +1.59% | -4.18% |
| YTD return | -29.91% | +8.87% |
| 1-year return | -46.96% | +52.31% |
| 5-year return | -84.09% | -67.37% |
| EPS (TTM) | $-0.55 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.48 | $39.53 |
| 52-week low | $1.30 | $15.32 |
| Distance from 52-week high | -54.17% | -44.95% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +291.85% | +252.16% |
| Average volume | 1.30M | 220.39K |
| Shares outstanding | 208.93M | 19.55M |
| Employees | 231 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed PROK by 99.3 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
PROK vs TECX FAQ
Which is bigger, ProKidney or Tectonic Therapeutic?
ProKidney (PROK) is larger, with a market capitalization of $636.70M compared with $425.39M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, PROK or TECX?
TECX returned +52.31% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.